Cancer Immunology, Immunotherapy

, Volume 60, Issue 8, pp 1147–1151

DNA fusion vaccines enter the clinic

  • Freda K. Stevenson
  • Ann Mander
  • Lindsey Chudley
  • Christian H. Ottensmeier
Focussed Research Review

DOI: 10.1007/s00262-011-1042-2

Cite this article as:
Stevenson, F.K., Mander, A., Chudley, L. et al. Cancer Immunol Immunother (2011) 60: 1147. doi:10.1007/s00262-011-1042-2

Abstract

Induction of effective immune attack on cancer cells in patients requires conversion of weak tumor antigens into strong immunogens. Our strategy employs genetic technology to create DNA vaccines containing tumor antigen sequences fused to microbial genes. The fused microbial protein engages local CD4+ T cells to provide help for anti-tumor immunity, and to reverse potential regulation. In this review, we focus on induction of CD8+ T cells able to kill target tumor cells. The DNA vaccines incorporate tumor-derived peptide sequences fused to an engineered domain of tetanus toxin. In multiple models, this design induces strong CD8+ T-cell responses, able to suppress tumor growth. For clinical relevance, we have used “humanized” mice expressing HLA-A2, successfully inducing cytolytic T-cell responses against a range of candidate human peptides. To overcome physical restriction in translating to patients, we have used electroporation. Clinical trials of patients with cancer are showing induction of responses, with preliminary indications of suppression of tumor growth and evidence for clinically manageable concomitant autoimmunity.

Keywords

DNA vaccinesCytotoxic T cellsProstate cancerCarcinoembryonic antigenPIVAC 10

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Freda K. Stevenson
    • 1
  • Ann Mander
    • 2
  • Lindsey Chudley
    • 3
  • Christian H. Ottensmeier
    • 3
  1. 1.Molecular Immunology Group, Cancer Sciences Division, Faculty of MedicineUniversity of SouthamptonSouthamptonUK
  2. 2.Cancer Sciences Division, Faculty of MedicineUniversity of SouthamptonSouthamptonUK
  3. 3.Experimental Cancer Medicine Centre, Cancer Sciences Division, Faculty of MedicineUniversity of SouthamptonSouthamptonUK